GenomeWebinars: CRISPR/Cas9 Strategies for Disease Modeling and Drug Discovery

This online seminar will outline emerging applications for the CRISPR/Cas9 system in disease modeling and therapeutic discovery. 

CRISPR/Cas9 is a revolutionary approach that enables rapid, economical model generation through precise genome editing. Every day, new studies continue to leverage the potential of CRISPR to generate novel strategies for modeling diseases and assessing therapeutic intervention. 

In this webinar, our panelists will discuss: 

• Strategies for high-throughput generation of mouse models (KO/KI) using CRISPR/Cas9 
• Special considerations for the use of the CRISPR/Cas9 system 
• Genetic manipulation of primary human T cells using CRISPR/Cas9 

Speakers: 

Alexander Marson, MD, PhD 

Research Fellow, UCSF Fellows Program 

Clinical Fellow, Division of Infectious Diseases, UCSF Medical Practice 

Alex Marson completed medical school at Harvard, PhD training at the Whitehead Institute/MIT, Internal Medicine residency at the Brigham and Women’s and clinical training in Infectious Diseases at UCSF. He is currently a UCSF Sandler Faculty Fellow and Principal Investigator in the UCSF Diabetes Center and Department of Medicine. Dr. Marson’s group integrates systems-scale investigations of human CD4+ T cell circuitry with functional perturbation studies, including genome editing in primary T cells. His work has employed genomic techniques to study the transcriptional circuits that enable immune cells to establish highly specialized identities. Now his lab is developing new tools for experimental and therapeutic genome engineering in human T cells. 

Bill Buaas, PhD 

Associate Director, Genetic Engineering Technologies 

The Jackson Laboratory 

Dr. Bill Buaas earned his Ph.D. from the University of Washington, investigating the molecular and genetic mechanisms of mammalian spermatogonial stem cell development. He continued studying mammalian reproduction and reproductive cancers in the United Kingdom as a postdoctoral researcher at The National Institute for Medical Research and The Institute of Cancer Research. He initially joined The Jackson Laboratory (JAX) as an Associate Research Scientist studying small non-coding RNA function in mammalian reproduction and development but went on to oversee the genomics next-generation sequencing service at JAX as the Associate Director. Bill joined the JAX Genetic Engineering Technologies group in 2015, where he and his team provide novel mouse model creation capabilities for researchers within JAX and beyond.